Phase Ib study of tirabrutinib in combination with idelalisib or entospletinib in previously treated chronic lymphocytic leukemia

AV Danilov, C Herbaux, HS Walter, P Hillmen… - Clinical Cancer …, 2020 - AACR
Purpose: Bruton tyrosine kinase (BTK) inhibition alone leads to incomplete responses in
chronic lymphocytic leukemia (CLL). Combination therapy may reduce activation of escape …
被引用次数：61 相关文章
[PDF] amazonaws.com

[PDF][PDF] Phase 1b Study of Tirabrutinib in Combination With Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia 2

AV Danilov, C Herbaux, HS Walter, P Hillmen, SA Rule… - pstorage-leicester-213265548798 …
5Experimental Haematology, University of Leeds, Leeds, UK 14 6Department of
Haematology, Plymouth University Medical School, Plymouth, UK 15 7Goshen Hospital …

Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia

AV Danilov, C Herbaux, HS Walter… - … : an official journal …, 2020 - pubmed.ncbi.nlm.nih.gov
Purpose Bruton tyrosine kinase (BTK) inhibition alone leads to incomplete responses in
chronic lymphocytic leukemia (CLL). Combination therapy may reduce activation of escape …

Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia

AV Danilov, C Herbaux, HS Walter, P Hillmen… - Clinical Cancer …, 2020 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: sec>< jats: title> Purpose:</jats: title>< jats: p>
Bruton tyrosine kinase (BTK) inhibition alone leads to incomplete responses in chronic …

Phase Ib study of tirabrutinib in combination with idelalisib or entospletinib in previously treated chronic lymphocytic leukemia

AV Danilov, C Herbaux, HS Walter… - Clinical Cancer …, 2020 - ohsu.elsevierpure.com
Purpose: Bruton tyrosine kinase (BTK) inhibition alone leads to incomplete responses in
chronic lymphocytic leukemia (CLL). Combination therapy may reduce activation of escape …

Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia.

AV Danilov, C Herbaux, HS Walter, P Hillmen, SA Rule… - 2020 - figshare.le.ac.uk
PURPOSE: Bruton tyrosine kinase (BTK) inhibition alone leads to incomplete responses in
chronic lymphocytic leukemia (CLL). Combination therapy may reduce activation of escape …

Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia.

AV Danilov, C Herbaux, HS Walter… - … Cancer Research: an …, 2020 - europepmc.org
Purpose Bruton tyrosine kinase (BTK) inhibition alone leads to incomplete responses in
chronic lymphocytic leukemia (CLL). Combination therapy may reduce activation of escape …

Phase Ib study of tirabrutinib in combination with idelalisib or entospletinib in previously treated chronic lymphocytic leukemia

AV Danilov, C Herbaux, HS Walter, MJS Dyer… - Clinical Cancer …, 2020 - elibrary.ru
Phase Ib study of tirabrutinib in combination with idelalisib or entospletinib in previously
treated chronic lymphocytic leukemia КОРЗИНА ПОИСК НАВИГАТОР ЖУРНАЛЫ КНИГИ …
[PDF] le.ac.uk

[PDF][PDF] Phase 1b Study of Tirabrutinib in Combination With Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia 2

AV Danilov, C Herbaux, HS Walter, P Hillmen, SA Rule… - figshare.le.ac.uk
5Experimental Haematology, University of Leeds, Leeds, UK 14 6Department of
Haematology, Plymouth University Medical School, Plymouth, UK 15 7Goshen Hospital …